Company Insights

BHC customer relationships

Explore interactive graphBrowse insights index
BHC customer relationship map

Bausch Health (BHC): Customer Relationships That Define Revenue Risk and Distribution Leverage

Bausch Health monetizes a diversified portfolio of prescription pharmaceuticals, medical devices and OTC products through a mix of direct promotion to health-care professionals and broad distribution channels; the company sells globally but generates the majority of revenue in North America, and it recognizes concentrated exposures where a handful of distributors and pharmacy benefit managers account for material shares of sales. For investors, the commercial thesis is straightforward: stable cash flows underpinned by entrenched supply relationships, offset by concentration risk tied to a small set of large customers and product-line concentration within specialty segments. If you want deeper counterparty-level intelligence for underwriting or portfolio diligence, see Null Exposure for full coverage: https://nullexposure.com/.

How Bausch Health actually reaches patients and customers

Bausch Health operates a hybrid go-to-market model. The company sells directly to physicians and hospitals through an internal sales force, and it routes the bulk of product volume through wholesalers, retail pharmacies and large drug chains where third-party payors and government reimbursement regimes determine net realized price. The firm’s product mix — eye health, gastroenterology (Salix), dermatology and Solta aesthetic devices — gives it multiple commercial channels but also creates single-product criticality in parts of the portfolio.

  • Global reach with North American concentration: Bausch reports product marketing in roughly 90 countries, but the U.S. and Puerto Rico accounted for ~60% of total revenue in 2024, concentrating revenue under U.S. payor dynamics.
  • Distribution-first sales posture: Trade receivables and revenue flows are primarily tied to wholesalers, pharmacies, government entities and group purchasing organizations, indicating a commercial model that relies on large intermediaries rather than purely retail-level sales.

These structural features translate directly into counterparty risk and negotiating leverage between BHC and its customers. If you want to explore relational exposure maps and document-level confirmation of these relationships, start here: https://nullexposure.com/.

Concentration and product-level criticality — what really matters

Top customers are not marginal — they represent a material portion of revenue. Bausch’s FY2024 disclosures show three customers each contributing double-digit shares: Cencora, McKesson and Cardinal Health. Separately, the Salix gastrointestinal franchise is a concentration point within the product portfolio; sales of the Xifaxan product line represent approximately 85% of Salix segment revenues, which creates product-level revenue dependence within that segment. These forces combine to produce a commercial profile that is powerful when distribution relationships are intact and risky when a major customer or product experiences disruption.

For a mid-deal diligence view focused on counterparty stability and receivables exposure, Null Exposure offers direct access to the filings and entity mappings: https://nullexposure.com/.

The three counterparties you must model now

Cencora Inc.

Cencora accounted for 19% of Bausch Health’s total revenue in 2024, a consistent top-tier customer across 2022–2024. According to Bausch Health’s 2024 Form 10‑K, Cencora represented 19% of revenues for 2024 and 2023 and 18% for 2022, marking it as the single largest customer in the period disclosed.

McKesson Corporation (MCK)

McKesson purchased 15% of Bausch Health’s revenue in 2024, unchanged from prior years, positioning McKesson as a stable distribution partner for a meaningful portion of sales. The FY2024 10‑K explicitly lists McKesson at 15% of total revenue in 2024, 2023 and 2022 (McKesson is traded under the symbol MCK).

Cardinal Health, Inc.

Cardinal Health accounted for 14% of total revenue in 2024, an incremental increase from 13% in prior years, confirming it as another large wholesale distribution customer for Bausch Health. Bausch Health’s 2024 Form 10‑K reports Cardinal Health at 14% for 2024 and 13% for 2023 and 2022.

(Each customer citation is drawn from Bausch Health Companies Inc.’s FY2024 Form 10‑K, where the company discloses customers representing 10% or more of total revenue.)

What the customer map implies for contracting posture and maturity

Bausch’s disclosures and related constraint signals show a supplier posture that is both buyer- and distributor-driven: the company sells through wholesalers and negotiates with large payors and group purchasing organizations, which concentrates pricing pressure and credit exposure. Company-level signals include:

  • Government reimbursement exposure — Bausch depends on reimbursements from governmental and other third‑party payors for certain product lines, exposing revenue to policy and programmatic pricing enforcement.
  • Large-enterprise counterparty dynamics — Bausch’s go-to-market requires sustained relationships and training for health-care professionals and large drug chains, producing dependence on established, large customers.
  • Global footprint with North American reliance — Marketing in ~90 countries creates geographic diversification, but revenue weighting toward the U.S. (60% in 2024) means U.S. payor dynamics dominate realized margin.
  • Distribution/reseller model maturity — The company primarily sells to wholesalers and, where it lacks a direct field presence, uses distributors; patient access and copay assistance channels add a reseller/residual retail component.
  • Product criticality — The Salix/Xifaxan concentration is a structural product risk within the portfolio and should be modeled separately from distribution counterparty risk.

These are company-level constraints derived from the 10‑K text and functional disclosures; they describe operating model characteristics investors must fold into revenue-forecast scenarios and counterparty credit assessments.

Investment implications and what to watch next

Key takeaway: Bausch Health’s revenue base is resilient but concentrated. The company benefits from entrenched wholesale channels and a global footprint, yet top customers alone comprised roughly 48% of 2024 revenue (19% + 15% + 14%), concentrating counterparty and pricing risk. Investors should prioritize three monitoring items:

  • Payer and government reimbursement policy developments in the U.S.
  • Contract renewals and price terms with the three large distributors and PBMs.
  • Sales trends within the Salix franchise and any regulatory or competitive threats to Xifaxan.

For practical underwriting workstreams and to map these relationships against public filings and receivables exposure, access the Null Exposure platform: https://nullexposure.com/.

Bottom line — risk-reward framed for operators and investors

Bausch Health delivers predictable sales through established distribution channels, but the combination of customer concentration, government payor exposure and product-level concentration in Salix elevates downside scenarios if a major counterparty changes procurement behavior or if regulatory shifts compress reimbursements. For investors, the opportunity lies in the company’s mature sales infrastructure and diversified product mix; the principal risk lies in concentrated counterparties and critical product dependence that can quickly reweight realized revenue.

If you need counterparty-verified evidence and document-level sourcing to underwrite these relationships, get started with Null Exposure: https://nullexposure.com/.